At a press conference at SABCS 2014, Dr Prudence Francis presents data on adding ovarian suppression to tamoxifen reduced recurrence for some women with premenopausal breast cancer.

A 35 percent decrease in risk of breast cancer recurrence was observed for premenopausal women who received chemotherapy for early-stage, hormone receptor-positive breast cancer and were assigned exemestane with ovarian suppression compared with those assigned tamoxifen.

Read the news story or watch the interview for more.